Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.58 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326616 | 1.00 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1HDAC3HDAC4 | |
| SCHEMBL4584382 | 1.00 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1HDAC3HDAC4 | |
| SCHEMBL4320869 | 1.00 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1HDAC3HDAC4 | |
| SCHEMBL2196275 | 1.00 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1HDAC3HDAC4 | |
| SCHEMBL4326621 | 1.00 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1HDAC3HDAC4 | |
| SCHEMBL2196280 | 1.00 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1HDAC3HDAC4 | |
| SCHEMBL4326629 | 1.00 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1HDAC3HDAC4 | |
| SCHEMBL4326613 | 1.00 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1HDAC3HDAC4 | |
| SCHEMBL4584380 | 1.00 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1HDAC3HDAC4 | |
| SCHEMBL4320871 | 1.00 | TRIM24 (0.58) | TRIM24TRIM33ALDH1A1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1038 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711010-A2 | PRO-PERFUME COMPOSITIONS | Firmenich SA (CH) | 2026-03-18 | — | — | EP | claimed |
| EP-4532659-B1 | LAUNDRY LIQUID COMPOSITION COMPRISING A SURFACTANT, AN AMINOCARBOXYLATE, AN ORGANIC ACID AND A FRAGRANCE | UNILEVER IP HOLDINGS B V (NL) | 2025-12-17 | — | — | EP | claimed |
| US-12290591-B2 | Fragrance compositions | FIRMENICH SA (CH) | 2025-05-06 | — | — | US | claimed |
| EP-4532659-A1 | LAUNDRY LIQUID COMPOSITION COMPRISING A SURFACTANT, AN AMINOCARBOXYLATE, AN ORGANIC ACID AND A FRAGRANCE | Unilever IP Holdings B.V. (NL) | 2025-04-09 | — | — | EP | claimed |
| EP-4519404-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | Firmenich SA (CH) | 2025-03-12 | — | — | EP | claimed |
| CN-119301230-A | Laundry liquid composition comprising surfactant, aminocarboxylate, organic acid and perfume | 联合利华知识产权控股有限公司 | 2025-01-10 | — | — | CN | claimed |
| EP-4438065-A2 | A MIXTURE COMPRISING 1,2-ALKANEDIOLS | Symrise AG (DE) | 2024-10-02 | — | — | EP | claimed |
| CN-113784759-B | Fragrance composition | 弗门尼舍有限公司 | 2024-07-05 | — | — | CN | claimed |
| US-20240199985-A1 | COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2024-06-20 | — | — | US | claimed |
| US-20240200000-A1 | COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2024-06-20 | — | — | US | claimed |
| US-20100247475-A1 | BETA-GLUCURONIDASE INHIBITOR | KAO CORPORATION (JP) | 2010-09-30 | — | — | US | claimed |
| US-20100152083-A1 | Perfume Systems | PROCTER & GAMBLE COMPANY, THE | 2010-06-17 | — | — | US | claimed |
| EP-2192178-A1 | B-GLUCURONIDASE INHIBITOR | Kao Corporation (JP) | 2010-06-02 | — | — | EP | claimed |
| US-7648955-B2 | perfume raw materials from specified classes such as 3-methoxy-p-hydroxybenzaldehyde; cosmetics, shampoo, body wash; long lasting fragrance | THE PROCTER & GAMBLE COMPANY (US) | 2010-01-19 | — | — | US | claimed |
| EP-1264594-B1 | Melanin production inhibitors and skincare products containing such inhibitors | TAKASAGO PERFUMERY CO LTD (JP) | 2006-11-29 | — | — | EP | claimed |
| WO-2005044206-A1 | FRAGRANCES COMPRISING RESIDUAL ACCORDS | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-19 | — | — | WO | claimed |
| US-20050096252-A1 | Fragrances comprising residual accords | PROCTER & GAMBLE COMPANY, THE | 2005-05-05 | — | — | US | claimed |
| US-6759557-B2 | MACROCYCLIC HYDROCARBON RINGS WITH HYDROXYL AND/OR KETONE FUNCTIONALITIES, SUCH AS CYCLOTETRADECANONE OR 2-HYDROXYCYCLOHEXADECANONE, OPTIONALLY WITH SKIN WHITENING AGENTS AND/OR UV ABSORBERS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-07-06 | — | — | US | claimed |
| US-20030049213-A1 | Melanin production inhibitors and skincare products containing such inhibitors | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-03-13 | — | — | US | claimed |
| EP-1264594-A2 | Melanin production inhibitors and skincare products containing such inhibitors | Takasago International Corporation (JP) | 2002-12-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030049213-A1 | Melanin production inhibitors and skincare products containing such inhibitors | TYR, AOC3, DOHH | TRIM24 444/4885TRIM33 4685/4885ALDH1A1 322/4885 |
| US-20100247475-A1 | BETA-GLUCURONIDASE INHIBITOR | GUSB, GAA, GANAB | TRIM24 1245/4885TRIM33 2450/4885ALDH1A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.